Kuros Biosciences to showcase new MagnetOs products at NASS 2021 Annual Meeting

. New products expand perioperative solutions for surgeons Data to be presented on new formulation of MagnetOs that includes a collagen carrier Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it will showcase new products in the MagnetOs range at the 36th Annual Meeting of the […]

continue reading

Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals

Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (NASDAQ: XOMA) under which XOMA has purchased a proportion of the potential future pre-commercial milestone payments and all the potential royalties due under the existing license […]

continue reading

Kuros Biosciences announces publication of data on MagnetOs in eCM Journal linking MOA to enhanced predictable bone regeneration

. First peer-reviewed article with demonstrated efficacy in preclinical and clinical studies  Outlines ability of MagnetOs to deliver uniform, stable and reliable bone fusions Kuros Biosciences (SIX: KURN) today announced the publication of new data in eCM Journal, a peer-reviewed publication focusing on preclinical re-search in the musculoskeletal field, on the mechanism of action of […]

continue reading

Kuros Biosciences to present at upcoming U.S. spine conferences

Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that high-profile surgeons will present on the STRUCTURE clinical trial with Fibrin-PTH and on preclinical and clinical data for MagnetOs bone graft at the upcoming 16th annual meeting of the Korean American […]

continue reading

Kuros Biosciences’s commercial roll-out of MagnetOs bone graft exceeds expectations

  MagnetOs U.S. Q1 sales accelerate, rising 117% over Q1 2020 European distribution network expansion ahead of schedule Key commercial events in Australia, UK Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today pro-vided an update on its commercial activities, with sales of MagnetOs bone graft and progress in establishing distributor […]

continue reading

Kuros to receive $4 million milestone payment from Checkmate Pharmaceuticals

. •    Milestone triggered by Checkmate’s initiation of potential registration trial of vidutolimod (CMP-001) in      patients with anti-PD-1 refractory advanced melanoma •    Kuros stands to receive up to $49 million additional milestones plus royalties on sales Kuros Biosciences (“Kuros”), a leader in next generation bone graft technologies, today announced it will receive a […]

continue reading

Kuros Biosciences strengthens its patent position on use of Fibrin-PTH in spinal fusion

Kuros Biosciences AG (SIX: KURN), a leader in next generation bone graft technologies, today announced that its subsidiary, Kuros Biosurgery AG, has been granted European patent EP 2686027, entitled ‘Pharmaceutical Formulation for Use in Spinal Fusion’.  This patent claims certain matrix materials in combination with parathyroid hormone (PTH) or derivatives of PTH. This patent strengthens […]

continue reading

Kuros Biosciences reports results for the full year 2020

Financial highlights CHF 29.8 million cash & cash equivalents, trade and other receivables at December 31, 2020 Revenues increased by 58% to CHF 4.0 million  Operational highlights Initiated Phase II clinical study of Fibrin-PTH in spine Commercial rollout in the U.S. and Europe on track Distribution agreements for The Netherlands, Austria, and Switzerland for MagnetOs […]

continue reading